What’s Next for U.S. CBD? Former Cop Weighs In
Days before Thanksgiving, the Food and Drug Administration (FDA) threw cold water on the red-hot American CBD boom.
It stated that CBD could be “potentially harmful.” And that more research needed to be done to determine its safety.
It was a frustrating moment for the industry.
That’s because, each day, it seems the U.S. is falling behind in the knowledge gap on CBD.
Israel and China are doing extensive research into cannabis and CBD.
The World Health Organization has stated that “there is no evidence of… any public health-related problems associated with the use of pure CBD.”
And even the National Institute on Drug Abuse deemed CBD a “safe drug with no addictive effects.”
But the FDA appears to be ignoring these resources.
My guest today – Andy Snyder, founder of Manward Press – actually testified before the FDA earlier this year about the safety of CBD.
Andy offers a unique perspective on cannabis and the CBD market. He was in law enforcement. He’s arrested people for marijuana.
But now he has a new mission. He’s seeking to educate consumers about the potential benefits that CBD can offer.
We sat down to discuss why he got involved in CBD, his take on the FDA’s decision and the issues facing hemp growers here in the U.S. Andy also shared what he wants to see at the federal level to bolster the industry and provide some much-needed research.
With the CBD market projected to be worth more than $20 billion over the next couple of years, this is an interview consumers and investors will want to check out.
Here’s to high returns,
Beyond the U.S.: Cannabis Investors Need to Think Bigger
December 17, 2020
What the Future Holds for the CBD Market
November 2, 2020
How Cannabis Companies Are Faring in the Wake of the Pandemic
August 18, 2020